Urology clinic setup cost in India: ₹35 L – ₹4 Cr, and why the endoscopy stack decides the return

Urology clinic setup cost in India runs from ₹35 L to ₹4 Cr, drawn from ICG's own engagement base across urology clients. ₹35 L buys a consulting-and-diagnostics practice: OPD, uroflowmetry, ultrasound, and every operative case referred out. ₹4 Cr buys a procedure centre with an endoscopy suite, laser lithotripsy, a day-care OT and its own imaging. The fork between them is unusually consequential here, because stone disease is high-volume, recurrent, and the single biggest driver of procedure demand a urology practice will ever see.

Contents

• Why stone disease makes urology a recurring-procedure business
• The referral network a stone practice needs before it needs a bigger building
• Durable capital versus consumed capital: what the endoscopy and lithotripsy stack actually is
• What happens to the return when the endoscopy suite can't turn over fast enough
• The scope reprocessing bottleneck, and the number of scopes it forces you to buy
• The equipment-first mistake: building the endoscopy suite before confirming the referral pipeline that fills it
• FAQ

Why stone disease makes urology a recurring-procedure business

Urology's economics rest on one structural fact: stone disease returns. A patient treated for calculi today has a real chance of forming another stone years later, and the condition is common enough across the population that a practice built around it can sustain procedure volume on its own, without the kind of marketing spend a purely elective specialty needs to keep filling a calendar. Urology clinic setup cost in India has to be read against that fact, because it's what makes the ₹35 L to ₹4 Cr fork unusually consequential rather than a simple bigger-or-smaller choice.

Few specialties combine high volume, genuine recurrence and heavy procedure load the way urology does. Cardiac care is episodic and high-ticket — one intervention, rarely a second. Orthopedics splits cleanly into surgical and conservative tracks that barely touch each other. Paediatrics runs on a scheduled-visit calendar, not on the same condition resurfacing in the same patient. Psychiatry is session-based, billed by the hour rather than the procedure. Urology is recurrent and procedural at the same time, which is why the equipment sitting behind that recurrence — not bed count, not consultation volume — is what actually separates the two ends of the range.

The referral network a stone practice needs before it needs a bigger building

Stone disease rarely walks in off the street looking for a urologist by name. It presents through family physicians managing a patient's first flank pain, through diagnostic centres reading an incidental ultrasound finding, and through emergency departments seeing a patient at 2am who has never heard of the clinic down the road. A urology practice's caseload is built on those referral relationships, not on direct search the way a cosmetic or elective specialty's caseload is.

That has a direct bearing on cost to start a urology clinic in India: two founders spending an identical ₹1.5 Cr on an identical endoscopy stack can land in very different places if only one of them has spent the eighteen months before launch building relationships with the physicians and diagnostic centres that actually see stone patients first. A referral network, once it exists, keeps sending cases with very little ongoing acquisition spend, because the condition itself keeps recurring in the same catchment. ICG's urology industry page covers the referral and positioning side of that question in more depth than a capital number alone can.

Durable capital versus consumed capital: what the endoscopy and lithotripsy stack actually is

A cystoscope lets a urologist see inside the bladder and lower urinary tract. A ureteroscope, thinner and longer, reaches up into the ureter to find and treat a stone directly. Laser lithotripsy, or shockwave lithotripsy as the non-invasive alternative, breaks the stone into fragments small enough to pass or retrieve. A C-arm gives the surgeon live fluoroscopic imaging while any of this is happening. Together, that stack is what separates a ₹35 L consulting practice from a ₹4 Cr procedure centre — everything else in the build is largely the same OPD and diagnostic infrastructure any clinic needs.

Unlike the orthopedic implant problem — inventory held on spec and possibly never billed to a patient — this is durable capital that amortises across every case it's used on rather than being consumed per case. A ureteroscope bought once keeps earning against every stone case it treats afterward, which is a different capital question entirely from stocking implant sizes a surgeon may never open.

A C-arm used for fluoroscopic guidance during these procedures triggers the same radiological safety clearance from the Atomic Energy Regulatory Board that a cath lab does. ICG's cardiac hospital setup cost breakdown walks through that clearance sequence in detail, so it isn't repeated here. AERB publishes no fee schedule for this clearance, so no cost figure is attributed to it.

• Cystoscope — durable, amortises across every diagnostic and follow-up procedure it's used in.
• Ureteroscope — durable, the core tool for the operative half of the range.
• Laser or shockwave lithotripsy platform — durable, the single highest line item in most builds.
• C-arm — durable, shared with the AERB clearance obligation above.

What a lithotripsy machine costs in India isn't a figure ICG has a verified source for this pass, and it shouldn't be estimated. What can be said with confidence is the structural point: this stack, not bed count or consultation-room count, is the capital decision that puts a build at ₹35 L or at ₹4 Cr. The same capital-planning logic that applies across specialties is laid out at ICG's clinic setup cost guide.

What happens to the return when the endoscopy suite can't turn over fast enough

Most endoscopic stone work is day-care, and that single fact changes what actually drives return in a urology procedure centre. It isn't beds. A day-care model means the patient is in and out the same day, so the number that matters is how many cases the endoscopy suite can turn over in a working day, not how many beds sit behind it collecting overnight charges nobody billed.

Urology clinic revenue in India, on the procedure side, is really revenue per endoscopy-suite slot, and that's a genuinely different constraint from the one an eye hospital carries. Ophthalmology's throughput argument turns on how many phaco cases move through an OT in a day, limited mainly by surgeon pace and turnaround between patients. Urology's turnover is capped by something ophthalmology's largely disposable-friendly instrument set never has to deal with: procedure-room turnaround plus the time it takes to get a reusable scope clean and ready for the next case. Two rooms with identical square footage and identical staffing can run at very different daily case counts depending on how that reprocessing loop is managed, a constraint the next section covers in full.

The table's time estimates are illustrative shape, not a published benchmark — every practice's real numbers depend on its own surgeon roster and reprocessing setup, neither of which is standard across the industry.

The scope reprocessing bottleneck, and the number of scopes it forces you to buy

Reprocessing doesn't cap how many stone cases a practice can treat in a month. It caps something narrower and more immediate: how many procedures a single flexible scope can support in one day. Flexible endoscopes need high-level disinfection between uses, a cycle that takes real time and takes the scope out of rotation while it happens.

That forces a genuine capital decision that has nothing to do with case volume in the abstract and everything to do with how many scopes a practice actually owns. A single-scope practice can only run as many procedures per day as its reprocessing cycle allows between cases, however many patients are waiting. Add a second scope, and the reprocessing cycle on one no longer idles the room while the other is in use. No reprocessing time and no scope price is stated here, because neither has a verified source for this pass — the number a given founder needs is set by their own expected case volume, not by a generic industry figure. Urology clinic break even moves directly with that decision, because a practice that under-buys scopes relative to its referral volume caps its own revenue with equipment it already paid for.

The equipment-first mistake: building the endoscopy suite before confirming the referral pipeline that fills it

Urology clinic investment in India goes wrong most often in one specific order: founders commission the full lithotripsy and endoscopy stack before the referral network that feeds it actually exists. The capital sits ready. The cases don't show up yet, because the physicians and diagnostic centres who would send them haven't been cultivated, and stone disease doesn't route itself to a new clinic by reputation alone in the first year.

The result is durable capital sitting idle against the very throughput and reprocessing constraints covered above — a scope stack bought to run at volume, running at a fraction of it, while the practice pays down equipment financed for a caseload that hasn't arrived. None of the three floor registrations a day-care urology practice needs changes this sequencing risk: Clinical Establishments Act registration, day-care surgical registration, and biomedical waste authorisation. None of these three carries a fixed central fee — the state notification, not the central Act, sets what a given clinic actually pays, and the Act's own classification provision confirms that the central government only prescribes categories, leaving the fee to the state.

PM-JAY does cover urological procedures, and its Health Benefit Package 2.2 manual states real, quotable rates: ₹1,800 per day for a routine ward stay, ₹2,700 for high-dependency care, ₹3,600 for intensive care without ventilator support, and a ₹1 lakh ceiling on any single unspecified-procedure package within an overall ₹5 lakh limit. Source: HBP 2.2 manual The manual states no urology-specific package rate, so nothing beyond these general figures should be assumed.

ICG's marketing engagement typically accounts for engagement-specific and clinic-model-dependent; see CPQL benchmarks for methodology of this clinic type's opex, benchmarked against no published specialty benchmark exists; see CPQL benchmarks for national average methodology — see ICG's CPQL benchmarks. What's measurable across the portfolio: ICG's healthcare clients have seen a 38-58% CPQL reduction within the first 90 days of onboarding, drawn from 46 active healthcare client engagements, a rolling 12-month window from July 2025 to July 2026, across Delhi NCR, Mumbai, Bangalore, Chennai, Hyderabad and Kolkata, last verified 26 July 2026.

FAQ

Meta Catalyst IQ SLC Framework view scoring Meta Ads accounts across Setup, Learning and Compounding phases with per-phase health metrics" width="1200" height="675" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

What's the realistic entry point to open a urology practice in India without an endoscopy suite? ₹35 L, drawn from ICG's own engagement base, buys OPD consultation, uroflowmetry and ultrasound, with every operative case referred out to a hospital the practice doesn't own. This is a genuinely standalone practice, not a scaled-down version of the procedure centre.

What does the full ₹4 Cr procedure-centre build actually include? It includes an endoscopy suite equipped with cystoscopes and ureteroscopes, laser or shockwave lithotripsy capability, a C-arm for fluoroscopic guidance, a day-care OT and its own imaging. The jump from ₹35 L isn't more consultation rooms — it's this equipment stack.

Does a urology clinic need an AERB licence? Yes, if a C-arm is used for fluoroscopic guidance during endoscopic procedures, the same way a cardiac cath lab does. ICG's cardiac hospital setup cost breakdown covers that clearance sequence in detail.

How many endoscopes does a urology practice actually need to run efficiently? It depends on expected case volume and how the practice manages scope reprocessing between cases, not on a fixed industry ratio. A single scope caps daily throughput at whatever the reprocessing cycle allows; a second scope removes that idle time between cases.

Is government or PM-JAY procedure volume worth taking on for a private urology clinic? PM-JAY's HBP 2.2 manual publishes ward and ICU per-bed-day rates and a ₹1 lakh unspecified-package ceiling within a ₹5 lakh limit, but states no urology-specific package rate. Any decision to take on scheme volume should be modelled against those general figures, not against an assumed urology-specific rate that doesn't exist in the published manual.

What's a realistic break-even timeline for a new urology clinic? It depends heavily on how quickly the referral network described above matures and how many scopes the practice owns relative to that volume, so there's no single published number. A practice that under-invests in either the referral side or the scope count will see its break-even clock stretch regardless of how much was spent on the core equipment stack.

What licences does a day-care urology surgical centre need before opening? Clinical Establishments Act registration, day-care surgical registration, and biomedical waste authorisation are the floor. None carries a fixed central fee — the state notification sets what's actually paid, not the central Act.

Is the lithotripsy or endoscopy stack the biggest line item in setup cost? It's the single largest driver of where a build lands between ₹35 L and ₹4 Cr, though ICG doesn't have a verified current price band for this pass.

Should a urology clinic build the endoscopy suite before securing a referral network, or after? After, or at minimum alongside it. Building the full stack first, before physicians and diagnostic centres are actually sending cases, is the single most common way founders end up with durable capital sitting idle against equipment they've already financed.

Written by Rohit Gupta, Co-Founder, Business & Growth Reviewed by Abhash Kumar, Co-Founder, Strategy

Neither the author nor the reviewer is a clinician; this is a capital-planning and marketing-economics analysis, not clinical or medico-legal advice.